Potent pre-clinical and early phase clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma
Nicosia, Luciano Brooks, N. Amaral, Fabio Sinclair, Oliver Pegg, N. A. West, W. Knurowski, T. Frese, K. Clegg, K. Cavet, James
Nicosia, Luciano
Brooks, N.
Amaral, Fabio
Sinclair, Oliver
Pegg, N. A.
West, W.
Knurowski, T.
Frese, K.
Clegg, K.
Cavet, James
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Nicosia L, Brooks N, Amaral F, Sinclair O, Pegg NA, West W, et al. Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma. Blood. 2022 Nov;140. PubMed PMID: WOS:000893223200349.